Obesity, insulin resistance and hepatic perfusion
Robert W Brock1, Robert B Dorman
1Department of Pharmacology & Toxicology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7199, USA. brockrobertw@uams.edu
Abstract:
Insulin resistance brings together the collection of hyperglycemia, hyperinsulinemia, and dyslipidemia associated with pathologies such as obesity and type 2 diabetes. As such, it is an important target for the prevention of complications linked with these pathologies. To the extent that insulin resistance involves hyperglycemia and dyslipidemia, there are obvious associations between impaired insulin signaling and microvascular dysfunction. In fact, there is evidence that insulin resistance significantly participates in the microvascular damage that occurs with obesity and type 2 diabetes. Since the liver plays a critical role in glucose homeostasis and lipid metabolism, and the state of the microcirculation reflects its function, the impact of insulin resistance on hepatic microvascular perfusion deficits is important. However, as of yet, no single body of work has addressed the relationships that exist between insulin resistance and the derangements in hepatic microvascular perfusion. Although there is distinct hepatic microvascular dysfunction associated with insulin resistance, a controversy still arises as to whether this dysfunction occurs as a result of reductions to the sinusoidal lumen. Nonetheless, the literature appears to agree that the general effects of obesity and insulin resistance on the hepatic microcirculation are linked to the selective impairment of phosphatidylinositol 3'-kinase signaling, as well as the presence of swollen fatty hepatocytes and sinusoidal "capillarization." This manuscript sets out to review the main aspects of hepatic glucose homeostasis and lipid metabolism, as well as the cellular and molecular mediators regulating hepatic microvascular perfusion deficits during obesity and insulin resistance.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Obesity
Type II Diabetes I: Introduction
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...


